Bora-Pharmaceuticals-Header Bora-Pharmaceuticals-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): SLN501

            Therapeutic Area: Immunology Product Name: SLN501

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Mallinckrodt Plc

            Deal Size: $2,020.0 million Upfront Cash: $20.0 million

            Deal Type: Collaboration April 28, 2021

            Details:

            The milestone relates to pre-clinical development work on the SLN500 C3 targeting program, highlighting the successful ongoing collaboration between the two companies.